Skip to content
LUNGevity Foundation· @LUNGevity · X·· 2026-04-21Score60

#SCLC

Reading

肺癌 — 围手术期 IO、KRAS NSCLC

Deep dive

发生了什么

AACR26会议现场有一场由LUNGevity Foundation安排的活动,其患者服务高级副总裁Ann Fish-Steagall(BSN、RN)登台,主题是患者倡导组织如何加速转化研究、提高临床试验入组,现场还会围绕SCLC(小细胞肺癌)与NEC的研究进展做专家讨论。据报道,Fish-Steagall负责的LUNGevity患者服务部门围绕四大患者外展支柱运作,涵盖支持、生存照护等方向[1]。

为什么重要

这场分享回答的是临床开发里的运营问题而不是疗效问题:在SCLC和NEC这类患者池有限的瘤种,入组速度直接卡着试验推进的节奏,患者组织的外展网络能不能真正变成入组渠道,是申办方和临床运营团队要拿主意的事。对正在设计或执行这类试验的团队,这是直接听倡导组织一线视角、判断要不要把患者组织纳入招募策略的机会;按支柱划分患者触达的做法,也可以搬到其他瘤种的入组路径设计里[1]。

还缺什么

帖子没有披露讲座的具体场次和时间,也没有给出SCLC与NEC研究进展的具体内容(涉及哪些试验、哪些数据),参与讨论的专家名单和是否有回放均待确认。下一步看AACR26期间SCLC与NEC方向各自披露的研究数据,以及LUNGevity是否借会议公布与试验入组挂钩的患者项目或合作安排,这些信息目前材料里都没有。

References
  1. 1.Senior Management · lungevity.org 2026
Body · original

Gaining a deeper understanding of molecular basis of chemoresistance in patients with #SCLC at #AACR26. REST, a promoter of neuroendocrine pathways, may be a strong target on the horizon for regulating anti-tumor activity. Interesting data by Dr. Jackson Fatheree from
@fredhutch

Heat 0 · 0 likes · 0 replies · 0 reposts

Conference abstracts
4618matched by 代号 TRI-611
TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases

Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella

Read the abstract →
CT014NCT04316364matched by 药名 adebrelimab
Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: Phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis

Yi-Long Wu, Wen-Zhao Zhong, Li-Xu Yan, Keneng Chen, Wanpu Yan, Yongzhong Luo, Wenxiang Wang, Wenqun Xing, Xiaolong Yan, Lin Wu, Feng Yao, Dongsheng Yue, Naiquan Mao, Yu Qi, Bentong Yu, Jianji Guo, Jindan Kai, Yuejun Chen, Hui Wang, Qin Zhang, Lunxu Liu, Honghai Wang, Yuanyuan Ji, Yongtao Han, Yongxiang Song, Jianjun Xu, Wei Guo, Hongxu Liu, Di Ge, Hecheng Li, XiuJuan Qu, Jifang Yao, Junfeng Liu, Tingyan Zhong, Yanhua Huang, Li Song, Wei Shi

Read the abstract →
CT038NCT05276609NCT06332170matched by 药名 adebrelimab
Combination of risvutatug rezetecan and adebrelimab in previously treated advanced nsq-NSCLC without actionable genomic alterations: Results from ARTEMIS-101, a phase 1 study

Hua Zhong, Haifeng Liu, Wei Zheng, Linlin Wang, Baogang Liu, Fangling Ning, Yongzhong Luo, Qiming Wang, Weiliang Zhu, Jianying Zhou, Qingwei Zhao, Ruoyu Wang, Xiang Li, Juan Li, Runbo Zhong, Yizhou Jin, Xiangru Mao, Jing Wang, Qingyuan Liu, Xiaoqing Zhang

Read the abstract →
CT140matched by 药名 ramucirumab
Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)

Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Maya Khalil, Brian S. Henick, James Moon, Pasarlai Ahmadzai, Michael LeBlanc, Daniel R. Carrizosa, Paul J. Hesketh, Ellen V. Sigal, Jeff Allen, Andreas N. Saltos, Bryan A. Faller, Roy S. Herbst, Charles D. Blanke, Jhanelle E. Gray

Read the abstract →

Source: LUNGevity Foundation · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org